378 companies receive BioNexus status, record RM25.6 billion in revenue

Malaysia's biotechnology sector is showing robust growth, with 378 companies having achieved BioNexus status since the program's inception in 2006. This recognition has collectively generated over RM25.6 billion in revenue and secured RM9.2 billion in export value to international markets.

The BioNexus status serves as a crucial platform designed to empower and strengthen local biotechnology firms. Companies that receive this designation gain access to essential business development support, opportunities for strategic collaborations, technical expertise, market access, and vital investment backing.

At the recent National Innovation and Commercialization Expo 2026 (NICE 2026), an additional 14 local biotech companies were awarded BioNexus status. This indicates a continued commitment to fostering high-potential companies and facilitating their development and investment pathways.

Mohd. Khairul Fidzal Abdul Razak, CEO of Bioeconomy Corporation, highlighted that the BioNexus framework, introduced in July 2025, has been refined to meet evolving industry needs and align with the National Biotechnology Policy 2.0. Key enhancements include a greater focus on government recognition, business development support, ecosystem access, and overall industry growth. Furthermore, the minimum paid-up capital requirement has been lowered from RM250,000 to RM150,000, broadening access for promising new companies.

Bioeconomy Corporation prioritizes building a community of high-quality, credible, and commercially viable BioNexus-status companies. The focus is not merely on increasing numbers but on identifying and supporting firms with strong innovations and significant potential for commercialization, export, technological advancement, and positive national impact. Collectively, BioNexus companies have created over 14,500 jobs and secured RM8.6 billion in approved investments, with nearly RM5 billion already implemented.